« Return to News | R&D Trends

Pathogenica, Illumina in co-marketing deal

Wednesday, July 17, 2013 12:30 PM

Pathogenica, a provider of medical diagnostic sequencing services and products, and Illumina have agreed to co-market in the Asia Pacific region a new version of Pathogenica's HAI BioDetection kit compatible with Illumina's MiSeq benchtop sequencing system. The combined solution will enable users to identify an expanded panel of bacteria and drug resistance genes present within clinical specimens and mixed cultures or isolates.

The kit will be a research-use-only test that enables identification and sub-typing of bacterial species responsible for over 95% of hospital acquired infections. The solution provides sequence-level resolution with automated analysis software in a multiplexed assay that makes hospital-wide surveillance practical. The solution has the capability to bypass the requirement of bacterial isolation and culture, expediting workflow, and can process 24-48 samples simultaneously per sequencing run.

"The introduction of an Illumina-compatible version of our kit emphasizes the platform-agnostic flexibility of our technology and allows us to reach new users in the large number of clinical-facing facilities keen to use Illumina's sequencing technology," said Yemi Adesokan, chief executive officer of Pathogenica.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.